| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:15261991 | IVTH | 0.000001 - 0.000025 M | 0.000001 - 0.000025 M | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations |
| PMID:15832825 | IVTH | 0.00005 M | 0.00005 M | Cancer phenotype | Endocrine-mediated cancer |
| IVTH | 0.000005 M | - | No significant effects observed | - | |
| IVTH | 0.0005 M | 0.0005 M | Cancer phenotype | Endocrine-mediated cancer | |
| PMID:22198180 | IVR | 0.6 mg/kg | 0.6 mg/kg | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations |
| IVR | 0.6 mg/kg | 0.6 mg/kg | Affects development of reproductive system | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.006 mg/kg | 0.006 mg/kg | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations | |
| PMID:28559116 | IVR | 0.006 mg/kg/day | 0.006 mg/kg/day | Compromised endometrial receptivity | Reproductive endocrine-mediated perturbations |
| IVR | 0.06 mg/kg/day | 0.06 mg/kg/day | Compromised endometrial receptivity | Reproductive endocrine-mediated perturbations | |
| PMID:33728745 | IVTH | 0.000001 M | 0.000001 M | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations |
| IVTH | 0.000001 M | 0.000001 M | Affects expression of androgen receptor (AR) | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000001 M | 0.000001 M | Cancer phenotype | Endocrine-mediated cancer | |
| PMID:34164426 | IVTH | 0.000005 - 0.00002 M | 0.000005 - 0.00002 M | Affects estrogen signaling | Reproductive endocrine-mediated perturbations |
| PMID:35051067 | IVTH | 0.0000001 - 0.000001 M | 0.0000001 - 0.000001 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:3827596 | IVR | 20 mg/L | 20 mg/L | Alterations in immune responses | Immunological endocrine-mediated perturbations |
| IVR | 20 mg/L | 20 mg/L | Changes in white blood cell (WBC) populations | Immunological endocrine-mediated perturbations | |
| IVR | 10 mg/L | 10 mg/L | Alterations in immune responses | Immunological endocrine-mediated perturbations | |
| IVR | 5 mg/L | - | No significant effects observed | - | |
| IVR | 10 mg/L | 10 mg/L | Changes in white blood cell (WBC) populations | Immunological endocrine-mediated perturbations | |
| PMID:39549571 | IVTH | 0.000001 - 0.00002 M | 0.000001 - 0.00002 M | Induced migration capability of tumor cells | Endocrine-mediated cancer |
| IVTH | 0.000001 - 0.00002 M | 0.000001 - 0.00002 M | Induce cancer metastasis | Endocrine-mediated cancer | |
| IVTH | 0.00001 - 0.00002 M | 0.00001 - 0.00002 M | Affects intracellular signaling pathway | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.00001 - 0.00002 M | 0.00001 - 0.00002 M | Cancer phenotype | Endocrine-mediated cancer | |
| PMID:8593856 | IVTH | 0.00001 M | 0.00001 M | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.